Skip to main content
OpenTrials
Completed

NCT Number: NCT01264198

The Role of Resistance Training in Non Alcoholic Fatty Liver Disease

The aim of the study is to evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tel Aviv Sourasky Medical center

Tel Aviv, 64239, Israel

About this study

Background: Non Alcoholic Fatty Liver Disease (NAFLD) is the most prevalent liver disease in developed countries with a prevalence rate of 20-30 % of adults. About 10-25% of these individuals are estimated to meet the current diagnostic criteria for Non Alcoholic Steatohepatitis (NASH) and some may progress to Cirrhosis and liver failure. NAFLD is now recognized as the hepatic manifestation of the metabolic syndrome. Recent data shows that NAFLD might also predict the tendency to develop diabetes mellitus and coronary artery disease. The drug of choice for NAFLD is yet to be found. The recommended treatment of NAFLD includes weight reduction and Physical Activity (PA), but the data of the effect of Resistance Training (RT) PA on NAFLD is scant.

Aim of the study: To evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD. Study design: Randomized Clinical Trial. Patients will be randomly allocated to 2 arms (intervention and control). The intervention arm will perform RT, whereas control arm will be advised to perform home stretching. Medical examination will be performed at week 0 (baseline) and at week 13 using uniform protocols.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ultrasound diagnosed fatty liver.

Exclusion criteria

  • Presence of HBsAg or anti-HCV antibodies (will be obtained from blood tests at the liver clinic).
  • Patients with known diabetes treated with antidiabetic medications.
  • Patients with known kidney disease, CHD, lung disease, inflammatory bowel disease.
  • Excessive alcohol consumption ≥ 30 g/day in men or 20 g/ day in women.

Treatment and study plan

Resistance training

Behavioral

Supervised Resistance Training

Primary outcomes

  1. The HRI value will be reduced in the intervention arm as compared to the The The change in Hepato-Renal Index (HRI) evaluated by ultrasound (US).

    Time frame: week 0 and week 13

Sponsors and collaborators

Lead sponsor

Tel-Aviv Sourasky Medical Center

Other Gov

Registry information

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Dec 21, 2010
Registry last updated
Mar 27, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.